1. Biochemistry and Chemical Biology
  2. Cancer Biology

Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction

  1. Jacob M Winter
  2. Heidi L Fresenius
  3. Corey N Cunningham
  4. Peng Wei
  5. Heather R Keys
  6. Jordan Berg
  7. Alex Bott
  8. Tarun Yadav
  9. Jeremy Ryan
  10. Deepika Sirohi
  11. Sheryl R Tripp
  12. Paige Barta
  13. Neeraj Agarwal
  14. Anthony Letai
  15. David M Sabatini
  16. Matthew L Wohlever
  17. Jared Rutter  Is a corresponding author
  1. Department of Biochemistry, University of Utah, United States
  2. Department of Chemistry & Biochemistry, University of Toledo, United States
  3. Whitehead Institute for Biomedical Research, United States
  4. Dana-Farber Cancer Institute, Harvard Medical School, United States
  5. University of Utah and ARUP Laboratories, United States
  6. Huntsman Cancer Institute, University of Utah, United States
  7. Department of Biology, Massachusetts Institute of Technology, United States
  8. Howard Hughes Medical Institute, United States
https://doi.org/10.7554/eLife.82860
Share this article
Cite this article
  1. Jacob M Winter
  2. Heidi L Fresenius
  3. Corey N Cunningham
  4. Peng Wei
  5. Heather R Keys
  6. Jordan Berg
  7. Alex Bott
  8. Tarun Yadav
  9. Jeremy Ryan
  10. Deepika Sirohi
  11. Sheryl R Tripp
  12. Paige Barta
  13. Neeraj Agarwal
  14. Anthony Letai
  15. David M Sabatini
  16. Matthew L Wohlever
  17. Jared Rutter
(2022)
Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction
eLife 11:e82860.
https://doi.org/10.7554/eLife.82860
  2. Download BibTeX
  3. Download .RIS

Abstract

The tumor suppressor gene PTEN is the second most commonly deleted gene in cancer. Such deletions often include portions of the chromosome 10q23 locus beyond the bounds of PTEN itself, which frequently disrupts adjacent genes. Coincidental loss of PTEN-adjacent genes might impose vulnerabilities that could either affect patient outcome basally or be exploited therapeutically. Here, we describe how the loss of ATAD1, which is adjacent to and frequently co-deleted with PTEN, predisposes cancer cells to apoptosis triggered by proteasome dysfunction and correlates with improved survival in cancer patients. ATAD1 directly and specifically extracts the pro-apoptotic protein BIM from mitochondria to inactivate it. Cultured cells and mouse xenografts lacking ATAD1 are hypersensitive to clinically used proteasome inhibitors, which activate BIM and trigger apoptosis. This work furthers our understanding of mitochondrial protein homeostasis and could lead to new therapeutic options for the hundreds of thousands of cancer patients who have tumors with chromosome 10q23 deletion.

Editor's evaluation

The authors identify co-deletion of the mitochondrial AAA+ ATPase ATAD1 with the tumor suppressor PTEN as a factor modifying cancer prognosis, based on a new mechanism of increasing sensitivity to proteotoxic stress induced by proteasome inhibition. The authors also identify the mitochondrial E3 ubiquitin ligase MARCH5 as a gene whose deletion is synthetically lethal with ATAD1. These findings suggest that the use of proteasome-targeting agents may be useful in patients with tumors dually deleted for ATAD1 and PTEN. The study is based on convincing evidence and makes an innovative contribution to the understanding of the biology of tumors with 10q23 deletions.

https://doi.org/10.7554/eLife.82860.sa0

eLife digest

Cancer cells have often lost genetic sequences that control when and how cell division takes place. Deleting these genes, however, is not an exact art, and neighboring sequences regularly get removed in the process. For example, the loss of the tumor suppressor gene PTEN, the second most deleted gene in cancer, frequently involves the removal of the nearby ATAD1 gene. While hundreds of thousands of human tumors completely lack ATAD1, individuals born without a functional version of this gene do not survive past early childhood. How can tumor cells cope without ATAD1 – and could these coping strategies become the target for new therapies?

Winter et al. aimed to answer these questions by examining a variety of cancer cells lacking ATAD1 in the laboratory. Under normal circumstances, the enzyme that this gene codes for sits at the surface of mitochondria, the cellular compartments essential for energy production. There, it extracts any faulty, defective proteins that may otherwise cause havoc and endanger mitochondrial health. Experiments revealed that without ATAD1, cancer cells started to rely more heavily on an alternative mechanism to remove harmful proteins: the process centers on MARCH5, an enzyme which tags molecules that require removal so the cell can recycle them. Drugs that block the pathway involving MARCH5 already exist, but they have so far been employed to treat other types of tumors. Winter et al. showed that using these compounds led to the death of cancerous ATAD1-deficient cells, including in human tumors grown in mice.

Overall, this work demonstrates that cancer cells which have lost ATAD1 become more vulnerable to disruptions in the protein removal pathway mediated by MARCH5, including via already existing drugs. If confirmed by further translational work, these findings could have important clinical impact given how frequently PTEN and ATAD1 are lost together in cancer.

Introduction

The tumor suppressor gene PTEN is deleted in more than 33% of metastatic prostate tumors and nearly 10% of glioblastoma multiforme and melanoma (Worby and Dixon, 2014). These deletions are imprecise and typically include PTEN as well as neighboring genes at the 10q23 locus. Prior research has demonstrated that the ‘collateral’ deletion of neighboring genes along with tumor suppressor genes can generate context-dependent vulnerabilities specific to tumor cells (Muller et al., 2015; Kryukov et al., 2016; Mavrakis et al., 2016). In some cases, such vulnerabilities can be exploited in a way that is toxic to mutant cancer cells but not to genetically intact host cells, which represents a therapeutic opportunity. Whether genomic deletions involving PTEN generate targetable vulnerabilities through the loss of neighboring genes is unknown, but would have relevance to a significant proportion of cancer patients given the frequency at which these deletions occur.

Only 40 kb upstream of PTEN is ATAD1, which encodes a AAA+ ATPase involved in protein homeostasis on the outer mitochondrial membrane (OMM) (Chen et al., 2014; Okreglak and Walter, 2014; Nakai et al., 1993; Wang and Walter, 2020; Zhang et al., 2011). ATAD1 hydrolyzes ATP to directly remove substrate proteins from the OMM (Wang and Walter, 2020; Wang et al., 2022). ATAD1 appears particularly suited to extract tail-anchored (TA) proteins, which harbor a C-terminal, single-pass transmembrane domain. In contexts unrelated to cancer, it has been shown that the absence of ATAD1 leads to the accumulation of TA proteins on the OMM and significant mitochondrial dysfunction (Chen et al., 2014). This housekeeping role of ATAD1 is important for cellular health, as evidenced by the findings that ATAD1 is essential for life in mammals and has been conserved over the 1 billion years of evolution separating yeast and humans (Zhang et al., 2011; Ahrens-Nicklas et al., 2017). Here, we describe how the collateral deletion of ATAD1 along with PTEN sensitizes cells to apoptosis induced by dysfunction of the ubiquitin proteasome system.

Results

ATAD1 and PTEN are co-deleted in many human cancers

Because the PTEN and ATAD1 genes are adjacent on human Chr10q23.31 (Figure 1A; Poluri and Audet-Walsh, 2018), we assessed whether ATAD1 is co-deleted with PTEN using immunohistochemistry on prostate adenocarcinoma tumors (Chung et al., 2019). We analyzed tumors that were PTEN-null by targeted sequencing, along with PTEN-wild-type (WT) controls. ATAD1 protein was undetectable in 21 of the 37 PTEN-null tumors analyzed, but was present in all 15 PTEN-WT control tumors (Figure 1—figure supplement 1A-C). Analysis of genomic data from The Cancer Genome Atlas corroborated these protein-level findings, as the majority of tumors harboring deep deletions in PTEN also had deep deletions in ATAD1 (Figure 1B). Importantly, ATAD1 is almost never deleted in the absence of PTEN deletion (Figure 1B), nor does it feature recurrent inactivating point mutations (Figure 1—figure supplement 1D,E), which argues that ATAD1 is not a tumor suppressor. Therefore, we hypothesize that ATAD1 deletion is simply a ‘hitchhiker’ with the oncogenic driver deletion of PTEN. These deletions most frequently span the 0.5 Mb surrounding PTEN, leading to collateral deletion of KLLN and RNLS in addition to ATAD1 (Figure 1—figure supplement 2). Altogether, ATAD1 is deleted at a high frequency across many tumor types, including in more than 25% of prostate cancer, 11% of melanoma, 7% of glioblastoma, and 4% of gastric adenocarcinoma (Figure 1C). Given the established role of ATAD1 in mitochondrial protein homeostasis, we hypothesized that a hitchhiker deletion of ATAD1 might confer unique vulnerabilities on tumors (Muller et al., 2015; Kryukov et al., 2016; Mavrakis et al., 2016; Muller et al., 2012).

Figure 1 with 4 supplements see all
Download asset Open asset
ATAD1 is co-deleted with PTEN in cancer and its loss confers synthetic lethal vulnerabilities.

(A) Schematic of PTEN and ATAD1 loci. (B) Oncoprint plots from three TCGA studies of cancer. ATAD1 and PTEN alteration frequencies are shown, with blue bars indicating deep deletions. (C) Frequency of ATAD1 deep deletions across various cancer types; data from cBioPortal. (D) CRISPR screen design for wild-type (WT) and ATAD1∆ Jurkat cells. (E) Jurkat CRISPR screen results; each point represents one gene. CRISPR score (CS) values were calculated by taking the average log2 fold-change in relative abundance of all sgRNAs targeting a given gene over 14 population doublings. WT CS values are shown on the y-axis. The CS values per gene for each of the two ATAD1∆ clones were averaged and are plotted on the x-axis. The top 10 genes that were differentially essential between WT and ATAD1∆ are labeled in blue, with MARCH5 labeled in red. (F) CRISPR screen design for HGC27 cells (Chr10q23 deletion, ATAD1-null) comparing gene essentiality in ATAD1 complemented cells or empty vector (EV) (ATAD1-null) control. (G) HGC27 CRISPR screen results; CS values are as described for (E). The x-axis depicts CS for the ATAD1-null condition of EV-transduced cells, and the y-axis depicts CS for the ATAD1-complemented (+ATAD1) condition. Labels are as described for (E).

Figure 1—source data 1

Source data used to make Figure 1.

https://cdn.elifesciences.org/articles/82860/elife-82860-fig1-data1-v3.zip

ATAD1 is synthetic lethal with MARCH5

We conducted genome-wide CRISPR knockout screens to identify genes that are selectively essential in ATAD1∆ cells. Such genes represent pathways whose inhibition could be selectively toxic to ATAD1-deficient tumor cells in a patient. We generated two ATAD1∆ clones in the PTEN-null Jurkat T-cell acute lymphoblastic lymphoma cell line using transient expression of Cas9 and one of two sgRNAs targeting distinct exons of ATAD1 (Figure 1—figure supplement 3A and B). Jurkat cells were chosen as an experimentally tractable system that has been validated in genetic screening and as a cell line with background PTEN deficiency. ATAD1 deletion did not affect basal proliferation rate (Figure 1—figure supplement 3C). We conducted parallel screens on the WT Jurkat parental cell line and each of the two ATAD1∆ clonal cell lines, the comparison of which enabled us to minimize idiosyncrasies inherent to clonal cell lines (Figure 1D). A CRISPR score (CS) is assigned to each gene, and represents the mean log2 fold-change in relative abundance of sgRNAs targeting that gene. CS values for the two ATAD1∆ clones were averaged and compared against those of the WT cells (Figure 1E). Genes that are selectively essential in the ATAD1∆ background represent ATAD1 synthetic lethal candidate genes. As expected, the differential CRISPR score (dCS) values for each ATAD1∆ clone vs. WT significantly correlated with each other (p=2.16 × 10–16; Figure 1—figure supplement 3D). The top 10 candidates for ATAD1 synthetic lethality include five genes that encode mitochondrial proteins (MARCH5, TAZ, MTCH1, TOP3A, DNM1L) and two components of the ubiquitin proteasome system (MARCH5, PSMC6), which are both processes with clear relevance to the known functions of ATAD1 (Calvo et al., 2016; Figure 1E). MARCH5 (also known as MITOL) was a particularly interesting hit, since it is an E3 ubiquitin ligase that promotes protein degradation on the OMM (Nakamura et al., 2006).

Many properties of cell lines can affect their particular genetic dependencies, including tissue of origin, driver, and passenger mutations, and even the media in which they grow (Hart et al., 2015; Rossiter et al., 2021). Therefore, we conducted an additional genetic screen in a different cellular context to gain a broader perspective on how ATAD1 deficiency creates synthetic lethal vulnerabilities. Rather than screening another pair of ATAD1-WT and engineered knockout cells, we sought to use cells that naturally have the Chr10q23 deletion seen in human tumors. Given the lack of available prostate cancer cell lines that harbor Del(10q23), we used a gastric adenocarcinoma cell line, HGC27, which is ATAD1 and PTEN deficient. ATAD1 is deleted in 4.1% of gastric cancer, a disease that causes nearly 800,000 deaths worldwide each year (Ferlay et al., 2019), therefore, we estimate that 32,000 patients die every year from ATAD1-deficient gastric cancer. This ranks second only to prostate cancer in terms of the number of deaths attributable to ATAD1-deficient tumors (Figure 1—figure supplement 4).

We made ATAD1-proficient and -deficient HGC27 lines by transducing with lentiviral ATAD1-FLAG or empty vector (EV), and subsequently conducted genome-wide CRISPR screens. In this case, genes that are selectively essential for EV cells (ATAD1-deficient) represent putative ATAD1 synthetic lethal candidate genes (Figure 1F). The top candidate for synthetic lethality with ATAD1 was MARCH5 (Figure 1G), a gene also identified in the Jurkat screen described above. Deletion of MARCH5 had a negligible effect on fitness in ATAD1-proficient HGC27 cells, but was an essential gene (by MAGeCK) in the EV cells (ATAD1-deficient). A second OMM-localized ubiquitin E3 ligase, MUL1, was also a top hit for synthetic lethality with ATAD1. In summary, our two complementary and unbiased genetic screens indicate that dysfunction of the ubiquitin proteasome system is preferentially lethal to cells lacking ATAD1.

We were particularly intrigued by the interaction of ATAD1 and MARCH5 for two main reasons. First, the same synthetic lethal interaction between ATAD1 and MARCH5 emerged as the top hit of CRISPR screens using two vastly different cellular contexts. Second, MARCH5 encodes a ubiquitin E3 ligase that ubiquitinates OMM proteins to trigger their extraction by p97/VCP and subsequent degradation by the proteasome (Nakamura et al., 2006; Cherok et al., 2017). MARCH5/p97 and ATAD1 mediate two parallel pathways by which OMM proteins are removed from mitochondria. Hence, it was intuitive that ATAD1 and MARCH5 could be synthetic lethal, given that they both contribute to protein homeostasis on the OMM, and synthetic lethal interactions classically involve two redundant pathways.

An imbalance of BCL2 family proteins underlies the synthetic lethality of ATAD1 and MARCH5

It has recently become clear that the key function of MARCH5 is to suppress apoptosis (Djajawi et al., 2020; Haschka et al., 2020; Subramanian et al., 2016; Arai et al., 2020). Apoptosis is regulated by OMM-localized BCL2 family proteins and requires the permeabilization of the OMM by BAX/BAK (Kale et al., 2018). Pro-survival proteins such as MCL1 bind to and inhibit BAX/BAK to prevent inappropriate cell death (Greaves et al., 2019). A variety of stressors activate BH3-only proteins (e.g. BIM), which trigger apoptosis by binding and inhibiting pro-survival proteins like MCL1 and in some cases by directly activating BAX/BAK (Letai, 2017). BH3-only proteins serve as sentinels for cellular stress and, upon activation, initiate mitochondrial outer membrane permeabilization (Bhatt et al., 2020; Llambi et al., 2011).

MARCH5 acts as a ‘guardian’ of MCL1 through an incompletely understood mechanism that involves the degradation of the pro-apoptotic BH3-only proteins BIM and/or NOXA (Kale et al., 2018; Letai, 2017; Llambi et al., 2011; Czabotar et al., 2014; Lin et al., 2022). We hypothesized that ATAD1 antagonizes these OMM-localized pro-apoptotic factors in parallel to MARCH5, such that simultaneous loss of both ATAD1 and MARCH5 leads to a lethal accumulation of pro-apoptotic proteins on the OMM. Indeed, BIM structurally resembles known substrates of ATAD1/Msp1 in that it is TA, has an intrinsically disordered region N-terminal to the transmembrane domain, and has basic residues at the extreme C-terminus (Castanzo et al., 2020; Li et al., 2019). Consistent with this hypothesis, the abundance of BIMEL (the predominant isoform of BIM) was increased in ATAD1∆ cells (Figure 2A). BIMEL can also be inactivated by phosphorylation by cytosolic kinases such as ERK. Deletion of ATAD1 decreased BIMEL phosphorylation, as assessed by decreased mobility in SDS-PAGE (Figure 2B), and with phospho-specific antibodies for residues Ser69 and Ser77 (Figure 2—figure supplement 1). While ATAD1 activity promoted the inhibitory phosphorylation of BIM at Ser69 and Ser77, it did not affect BIM phosphorylation at Thr112, a phosphorylation site that potentiates the pro-death activity of BIM (Figure 2—figure supplement 1). These data suggested that ATAD1 might act on BIM to promote its degradation and inhibitory phosphorylation.

Figure 2 with 9 supplements see all
Download asset Open asset
ATAD1/MARCH5 synthetic lethality is partially mediated by BIM, which is a novel ATAD1 substrate.

(A) Western blot of Jurkat cell lines, with quantification of BIMEL levels normalized to alpha-tubulin; one sample t and Wilcoxon test. (B) Western blot of whole cell lysates from wild-type (WT) or ATAD1∆ Jurkat cells stably expressing sgNT or sgBIM with Cas9-T2A-GFP. Lysates were mock treated or treated with lambda phosphatase (λ PPase) and analyzed by PhosTag/SDS-PAGE. (C) Western blots of Jurkat cell lines stably expressing Cas9-T2A-GFP with sgNT or sgBIM, harvested 4 days after transduction with additional indicated sgRNAs. (D) Viability of Jurkat cells after deletion of MARCH5, using different genetic backgrounds. Viability at 4 days post-transduction was normalized to that of cells transduced with sgRNA targeting AAVS1. Data analyzed by two-way ANOVA with Tukey’s multiple comparisons. (E) Viability of Jurkat cells stably expressing GFP or Myc-tagged MCL1 after deletion of MARCH5 and normalized as in (D). (F) Viability of Jurkat cells transduced with tetracycline-inducible GFP or GFP-BIMEL fusion; t=48 hr, normalized to viability of cells without doxycycline. (G) Western blot of cell lines as described in (D), treated with doxycycline (Dox) for 24 hr. (H) Schematic of in vitro extraction assay; ‘Ni2+ lipos’ indicates the use of nickel chelating headgroups of lipids in the liposomes; the star symbolizes a GST tag on the soluble chaperones, calmodulin (CaM) and SGTA, which are included to catch extracted TA substrates. (I) Extraction assay using His-ATAD1 and 3xFLAG-BIML (lanes 1–8, 13–20) or the negative control yeast TA protein, 3xFLAG-Fis1p (lanes 9–12); E193Q indicates the use of a catalytically inactive mutant of ATAD1; in samples shown in lanes 5–8, Ni2+ chelating lipids were omitted; in samples shown in lanes 17–20, ATP was omitted; ‘I’=Input, ‘FT’=flow-through, ‘W’=final wash, ‘E’=elution. Eluted fractions represent TA proteins extracted by ATAD1 and bound by GST-tagged chaperones; compare elution ‘E’ to input ‘I’. (J) Extraction assay as described in (H) but comparing different BH3-only proteins, BIM, BIK, and PUMA. (K) Quantification of assays as shown in (I), n=6 independent experiments.

Figure 2—source data 1

Source data and uncropped blots used to make Figure 2.

https://cdn.elifesciences.org/articles/82860/elife-82860-fig2-data1-v3.zip

Since MARCH5 regulates the BIM/NOXA/MCL1 axis, we assessed abundance of these proteins in the context of single and double deletion of ATAD1 and MARCH5. Deletion of ATAD1 increased BIM levels, while deletion of MARCH5 increased NOXA levels (Figure 2C). Accordingly, deletion of both MARCH5 and ATAD1 increased the abundance of both NOXA and BIM, which work together to antagonize the pro-survival protein MCL1 (Figure 2C). We hypothesized that synergistic antagonism of MCL1 explained, at least in part, the synthetic lethality of ATAD1 and MARCH5.

We tested whether BIM was required for the synthetic lethal interaction of ATAD1 and MARCH5. Deletion of MARCH5 caused a modest decrease in viability in WT Jurkat cells (Figure 2D). This effect was similar when we deleted MARCH5 in polyclonal BIM (BCL2L11) knockout cells (Figure 2D; generated by stably expressing Cas9 and sgRNA targeting BCL2L11). ATAD1∆ cells, however, were hypersensitive to MARCH5 deletion, as expected from our CRISPR screen results. Interestingly, BIM knockout partially rescued the hypersensitivity of ATAD1∆ cells to MARCH5 deletion (Figure 2D). These results validate the major finding from our CRISPR screens and demonstrate that BIM is partially responsible for the synthetic lethality of ATAD1 and MARCH5.

If MCL1 antagonism underlies ATAD1/MARCH5 synthetic lethality, then we reasoned that overexpression of MCL1 might rescue this phenotype. Indeed, we found that the synthetic lethal interaction of ATAD1 and MARCH5 was suppressed in cells stably overexpressing MCL1 (Figure 2E). Again, we observed increased BIMEL and NOXA in ATAD1∆ cells, and deletion of MARCH5 led to a further increase in NOXA levels (Figure 2—figure supplement 2A). These effects were limited in cells overexpressing MCL1, which may reflect regulation of NOXA degradation by MCL1 binding. As a positive control for testing gene essentiality, we transduced cells with an sgRNA targeting the pan-essential gene PCNA, which is necessary for DNA replication (Girish and Sheltzer, 2020). Deletion of PCNA was similarly toxic to WT and ATAD1∆ cells, and was not rescued by BIM deletion nor by MCL1 overexpression (Figure 2—figure supplement 2B and C). These data indicate that ATAD1 protects cells from MARCH5 deletion specifically, rather than making them generally more resistant to perturbation of important genes.

Altogether, our CRISPR screens identified a synthetic lethal interaction between ATAD1 and MARCH5, both of which enact protein extraction from the OMM. Loss of ATAD1 and MARCH5 antagonizes the anti-apoptotic function of MCL1 via increased abundance and activity of BIM and NOXA, which partially explains the synthetic lethality.

We next asked if BIM was sufficient to trigger apoptosis preferentially in ATAD1∆ cells. We generated Jurkat cell lines expressing a tetracycline-inducible GFP-BIMEL fusion protein. The dose-dependent increase in GFP-BIM expression was equivalent in WT and ATAD1∆ cells (anti-GFP blot, Figure 2F). Maximal expression of GFP-BIMEL using 500 ng/mL doxycycline killed cells regardless of the presence or absence of ATAD1 (Figure 2G; Figure 2—figure supplement 3A). However, ATAD1∆ cells were hypersensitive to intermediate expression of ectopic BIMEL, as measured by cell viability assays (Figure 2G), cleaved PARP immunoblots (Figure 2F), and live cell imaging using the Incucyte platform (Figure 2—figure supplement 3A). Thus, endogenous ATAD1 protects against BIM but ATAD1 can be overwhelmed with sufficiently high levels of BIM. These results demonstrate that BIM is sufficient to induce apoptosis preferentially in cells lacking ATAD1. We further studied how ATAD1 affected apoptotic priming (the propensity of a cell to undergo intrinsic apoptosis) using BH3 profiling. H4 glioma cells (Del(10q23); ATAD1-null; Figure 2—figure supplement 3B) were highly sensitive to BIM peptide, which is rescued by re-expression of ATAD1WT but not the catalytically dead ATAD1E193Q mutant (Figure 2—figure supplement 3C). ATAD1 therefore appears to suppress overall apoptotic priming, at least in this context, as measured by sensitivity to BIM BH3 peptide.

ATAD1 directly and specifically extracts BIM from membranes

We hypothesized that BIM might be a direct substrate of the ATAD1 dislocase, which could explain how ATAD1 suppresses BIM-induced apoptosis. Consistent with BIM being an ATAD1 substrate, GFP-BIMEL co-immunoprecipitated with FLAG-tagged ATAD1 in H4 cells (Figure 2—figure supplement 3D). Inversely, ATAD1-FLAG co-immunoprecipitated with endogenous BIM (Figure 2—figure supplement 3E). Thus, reciprocal co-immunoprecipitation argues that ATAD1 and BIM physically interact in cells.

We further tested whether ATAD1 can directly extract BIM from a membrane using an in vitro system with purified components (Wohlever et al., 2017). We used BIML because it is more soluble than BIMEL but shares the key structural features that would likely mediate ATAD1 recognition, including the tail-anchor and juxtamembrane regions (Ley et al., 2005; Liu et al., 2019; Chi et al., 2020). We were unable to purify active, full-length ATAD1. Instead, we swapped the N-terminal transmembrane domain with a His6 tag, which anchored His6-ATAD1 to liposomes doped with phospholipids containing nickel-chelated headgroups (‘Ni Lipos’, Figure 2H). In this extraction assay, TA proteins that are extracted from liposomes by ATAD1 bind soluble GST-tagged chaperones (SGTA and calmodulin), which are purified on a glutathione column and detected by immunoblotting (Figure 2H; Wohlever et al., 2017). We validated the Ni-His anchoring strategy using full-length or truncated yeast Msp1 (the yeast homolog of ATAD1) and positive and negative control substrates (Figure 2—figure supplement 4A–C).

His6-ATAD1 directly and efficiently extracted 3xFLAG-BIML from liposomes in this assay (Figure 2I; compare lanes with elution ‘E’ to input ‘I’; lanes 13–16). As expected, this activity was ATP-dependent (Figure 2I, lanes 17–20) and was abolished when we used the catalytically inactive mutant, ATAD1E193Q (Figure 2I, lanes 1–4). Omission of Ni-chelating lipids from the liposomes (‘Mito Lipos’, which cannot anchor His6-ATAD1; Figure 2I, lanes 5–8) prevented ATAD1 from extracting BIM, demonstrating that ATAD1 requires membrane anchoring for its dislocase activity. Importantly, ATAD1 did not extract yeast Fis1, consistent with previous reports that Fis1 is not an Msp1 substrate (Li et al., 2019; Figure 2I, lanes 9–12).

Many BH3-only proteins share key structural features, including a tail-anchor, so we next asked whether ATAD1 could extract other members of this protein family (Wilfling et al., 2012). In addition to BIM, we tested BIK, PUMA, and NOXA, since these have been proposed to mediate apoptosis triggered by proteotoxic stress. NOXA did not incorporate into proteoliposomes, which precluded it from our assay, and is consistent with a report that it lacks a transmembrane domain (Andreu-Fernández et al., 2016). ATAD1 extracted BIM in an ATP-dependent manner, as expected, but failed to extract BIK or PUMA under the same conditions (Figure 2J and K). While it is not clear how ATAD1 distinguishes between these substrates, BIM differs from BIK and PUMA in that it has a positively charged C-terminus and an intrinsically disordered region N-terminal to the transmembrane domain, which are important features for substrate recognition by Msp1, the yeast homolog of ATAD1 (Figure 2—figure supplement 5; Castanzo et al., 2020; Li et al., 2019). Taken together, we demonstrate that ATAD1 and BIM physically and genetically interact in cells, and that ATAD1 can directly extract BIM – but not other, related, BH3-only proteins – from membranes in a reconstituted system.

These data raise the question of what happens to BIM after it has been extracted by ATAD1. We transduced SW1088 cells, which are a Del(10q23) cell line suitable for imaging, with either EV or ATAD1-FLAG. These cells were then transduced with TetON(GFP-BIMEL∆BH3), in which four point mutations in the BH3 domain of BIM neutralize its pro-apoptotic activity to permit live cell imaging. We assessed GFP-BIMEL∆BH3 localization using live cell confocal microscopy in the presence and absence of ATAD1, using MitoTracker Red to label mitochondria. ATAD1 altered the localization of BIM under basal conditions, generating GFP-positive puncta that did not colocalize with mitochondria (Figure 2—figure supplement 6A). Since BIM is regulated by proteasomal degradation, we additionally treated cells with bortezomib, a proteasome inhibitor. Treatment with bortezomib exacerbated this phenotype and resulted in larger, brighter GFP-positive puncta only in ATAD1 expressing cells (Figure 2—figure supplement 6B and C). We saw the same phenomenon when we genetically labeled mitochondria with mCherry, ruling out the possibility that these GFP-BIM puncta are merely depolarized mitochondria that cannot accumulate Mitotracker dye (Figure 2—figure supplement 7). GFP-positive puncta also did not colocalize with lysosomes or peroxisomes (Figure 2—figure supplements 8 and 9). In addition to localization, BIM is regulated by inhibitory phosphorylation, which we had previously observed to be affected by ATAD1 status. Bortezomib treatment led to the accumulation of phosphorylated BIMEL in SW1088 cells expressing ATAD1, while BIMEL accumulated in an unphosphorylated state in SW1088 cells transduced with EV (Figure 3—figure supplement 1A). We next used the PC3 prostate cancer cell line, which is PTEN-null and has a partial deletion of ATAD1 (Figure 3—figure supplement 1B). In parallel to our findings with SW1088 cells, BIM accumulated in a phosphorylated state after treatment with bortezomib in PC3 cells with ATAD1 present (sgNT), but this phosphorylation was abrogated in PC3 cells with ATAD1 deleted (Figure 3—figure supplement 1C and D). Thus, in the context of proteasome inhibition, ATAD1 shifts the localization of BIM from mitochondria to cytoplasmic puncta and promotes inhibitory phosphorylation of BIM.

Proteasome inhibition is preferentially toxic to ATAD1-deficient cells

We next sought to pharmacologically exploit ATAD1 deficiency in relevant cancer models, drawing on our discovery of synthetic lethality with MARCH5. Since MARCH5 is a ubiquitin E3 ligase, we hypothesized that disrupting the ubiquitin proteasome system downstream of MARCH5 might also be preferentially toxic to cells lacking ATAD1. Consistent with this idea, proteasome inhibitors are known to increase BIM and NOXA abundance, thereby triggering apoptosis (Baou et al., 2010; Meller et al., 2006). There were hints from our CRISPR screens that ATAD1-deficient cells might be more sensitive to ubiquitin proteasome system dysfunction generally, with PSMC6 (encoding a proteasome subunit; Jurkat screen) and MUL1 (encoding a mitochondrial E3 ligase; HGC27 screen) also scoring among the top hits for synthetic lethality (Figure 1E and G).

Re-expression of ATAD1 in the Del(10q23) cell lines HGC27 (gastric cancer), SW1088 (glioma), or RPMI7951 (melanoma) suppressed toxicity caused by various structurally distinct proteasome inhibitors (Figure 3A–C, Figure 3—figure supplement 2A–E). That the phenotype was common to multiple proteasome inhibitors with different mechanisms of action increases our confidence that this is due to an on-target effect. Deletion of ATAD1 increased sensitivity to bortezomib in PC3 cells (Figure 3D). Inversely, overexpressing ATAD1WT, but not ATAD1E193Q, made PC3 cells more resistant to bortezomib (Figure 3—figure supplement 2F).

Figure 3 with 4 supplements see all
Download asset Open asset
ATAD1 protects cells from apoptosis triggered by proteasome inhibition.

(A) Viability of HGC27 cells treated with bortezomib (BTZ) for 16 hr. (B) Viability of SW1088 cells treated with BTZ for 24 hr. (C) Viability of SW1088 cells treated with carfilzomib, a different proteasome inhibitor, for 24 hr. (D) Viability of PC3 cells treated with BTZ for 16 hr. (E) Western blots of HGC27 cells screen treated with 1 µM BTZ for 16 hr. (F) Western blots of SW1088 cells transduced with empty vector (EV) or ATAD1-FLAG and treated with 100 nM BTZ for 16 hr. (G) Western blots of PC3 cells transduced with non-targeting sgRNA or ATAD1 sgRNA and treated with 1 µM BTZ for 16 hr. (H) Viability as measured by normalized crystal violet staining (Abs 590 nm) in PC3 cells transduced with sgNT vs. sgATAD1, treated with BTZ for 16 hr in the presence or absence of 40 µM zVAD-FMK. Data analyzed by two-way ANOVA with Tukey’s multiple comparisons.

Figure 3—source data 1

Source data used to make Figure 3.

https://cdn.elifesciences.org/articles/82860/elife-82860-fig3-data1-v3.zip

We hypothesized that apoptosis was responsible for the sensitivity of ATAD1-deficient cells to proteasome inhibition. Indeed, bortezomib treatment induced robust PARP cleavage in the same ATAD1-deficient cells described above, but not in cognate ATAD1-positive cells (Figure 3E–G, Figure 3—figure supplement 3A-C). Bortezomib treatment caused polyubiquitinated proteins to accumulate to the same extent in the presence or absence of ATAD1, indicating that ATAD1 affects how the cell responds to proteotoxic stress, rather than blocking the proteotoxic insult itself (Figure 3E–G, Figure 3—figure supplement 3B). Thus, ATAD1 appears to be essential for viability in cells subjected to ubiquitin proteasome system dysfunction.

Apoptotic cell death is only one of many mechanisms underlying proteasome inhibitor toxicity (Tsvetkov et al., 2019; Schneider and Bertolotti, 2015; Huang et al., 2020). We next asked whether ATAD1 affects proteasome inhibitor sensitivity via some apoptosis-independent pathway, in which case ATAD1 re-expression and caspase inhibition (which blocks apoptosis) would have an additive effect in mitigating proteasome inhibitor toxicity. Treatment of ATAD1 knockout PC3 cells with the caspase inhibitor zVAD-FMK rescued the effects of bortezomib essentially back to WT levels (Figure 3H; Figure 3—figure supplement 3E). Additionally, ATAD1 re-expression phenocopied treatment with zVAD-fmk in RPMI7951 cells (Del(10q23)) treated with bortezomib (Figure 3—figure supplement 3F and G). Moreover, there was no additive effect of zVAD-fmk and ATAD1, suggesting that ATAD1 and zVAD-fmk act in a linear pathway to prevent the death of cells subjected to proteasome inhibition (Figure 3H, Figure 3—figure supplement 3G and H).

Although caspase inhibition completely rescued the bortezomib phenotype of ATAD1-deficient cells, the same was not true for deletion of BIM in PC3 cells, implying that other factors in addition to BIM mediate this phenotype (Figure 3—figure supplement 4A and B). We examined several OMM-localized or TA proteins in PC3 cells with and without bortezomib, and reduced BIM phosphorylation was the only consistent change caused by ATAD1 deletion (Figure 3—figure supplement 4C). Other BH3-only proteins reported to be activated by proteotoxic stress include BIK, PUMA, but our in vitro extraction assay ruled out a direct action of ATAD1 to extract these proteins. Increased mitochondrial fragmentation in ATAD1-null cells could be one potential explanation, since mitochondrial dynamics are intimately connected to apoptosis (Chen et al., 2014). Nonetheless, these results indicate that the protective effects of ATAD1 during proteasome inhibition can be explained exclusively by limiting apoptosis, with BIM extraction playing a key role.

ATAD1 loss limits tumor progression, particularly under proteotoxic stress

We next tested whether deficiency of ATAD1 sensitized cancer cells to proteasome inhibition in mouse tumor xenografts. Bortezomib had no effect on growth of PC3 xenografts transduced with sgNT, but significantly decreased the growth rate of tumors in which ATAD1 was deleted (Figure 4A and B). Bortezomib treatment induced a significant increase in NOXA levels in sgATAD1 tumors, but not in sgNT tumors (Figure 4C; Figure 4—figure supplement 1). NRF1/TCF11 is a transcription factor that is activated upon proteasome dysfunction, and we measured NRF1 levels by immunoblot to assess bortezomib activity (Radhakrishnan et al., 2010). NRF1 was equally induced by bortezomib in sgNT and sgATAD1 tumors (Figure 4C; Figure 4—figure supplement 1), again supporting our conclusion that ATAD1 protects cells from death triggered by protein stress rather than preventing the protein stress itself. Altogether, these in vivo results demonstrate that bortezomib is preferentially toxic to PC3 tumors that lack ATAD1.

Figure 4 with 2 supplements see all
Download asset Open asset
ATAD1 loss sensitizes PC3 xenografts to proteasome inhibition and predicts improved survival in patients with metastatic prostate cancer.

(A) Tumor volume over time for mice with flank xenografts of PC3 cells treated with saline (vehicle) or 1 mg/kg bortezomib (BTZ). (B) Tumor volume over time for mice with flank xenografts of ATAD1-knockout PC3 cells treated with saline (vehicle) or 1 mg/kg BTZ. (C) Western blots of whole cell lysates from tumor samples taken from animals as in (A,B) sacrificed 24 hr after receiving saline/BTZ. (D) Kaplan-Meier curve of overall survival from patients with metastatic, castrate-resistant prostate cancer (mCRPC), stratified based on tumor genotype at the ATAD1 and PTEN loci, with accompanying table below. (E) Survival (months) after initiating chemotherapy or hormone therapy (F) in patients with mCRPC, based on tumor genotype. (G) Graphical summary.

Figure 4—source data 1

Source data used to make Figure 4.

https://cdn.elifesciences.org/articles/82860/elife-82860-fig4-data1-v3.zip

ATAD1 was not necessary for basal tumor growth in PC3 cells, so we assessed the effect of ATAD1 on tumor growth of SW1088 cells, a Del(10q23) glioma cell line that is non-tumorigenic in SCID mice (Jiang et al., 2017; Mercapide et al., 2003). As expected, SW1088 cells transduced with EV failed to form tumors in 17 out of 17 NOD/SCID mice. However, SW1088 cells transduced with ATAD1 grew palpable tumors in 20 out of 21 mice (Figure 4—figure supplement 2A and B). ATAD1 thus promotes growth of SW1088 glioma xenografts, despite not affecting their proliferation in 2D culture (Figure 4—figure supplement 2C).

Finally, we examined clinical outcomes in patients with tumors that were (i) PTEN-null, (ii) both PTEN-null and ATAD1-null, or (iii) neither (‘unaltered’ at these loci). We queried two studies of patients with metastatic, castration-resistant prostate cancer (mCRPC) (Robinson et al., 2015; Abida et al., 2019). The median overall survival of mCRPC patients with PTEN-null ATAD1-null tumors (77 months) was more than double that of patients with only PTEN-null or ‘unaltered’ tumors (37 months, Figure 4D). In a subset of patients, we were able to additionally assess overall survival after initial hormone therapy or chemotherapy. Patients whose tumors lacked both ATAD1 and PTEN had longer survival post-therapy than did the patients whose tumors lacked only PTEN (Figure 4E and F). Altogether, these data suggest that ATAD1 exerts a pro-survival effect in tumor cells (with ATAD1 deficiency decreasing tumor fitness and improving patient survival) in both murine xenografts and human mCRPC patients.

Discussion

In this work we describe how the collateral deletion of ATAD1, a mitochondrial protein extractase, sensitizes cancer cells to apoptosis induced by proteasome dysfunction. It might appear counterintuitive that ATAD1 protects against apoptosis despite Chr10q23 deletion occurring so frequently in cancer. This may be partly explained by the strong selection for deletion of PTEN, which virtually always co-occurs with deletion of ATAD1. PTEN loss activates AKT, which has pro-survival effects, including decreasing transcription of BCL2L11 (BIM) by inhibiting FOXO3A, and inactivating the BH3-only protein BAD by direct phosphorylation (Gilley et al., 2003; Datta et al., 1997). Therefore, co-deletion of PTEN likely buffers some of the apoptotic priming induced by ATAD1 loss. Even so, neutral or detrimental alleles that act as genetic ‘hitchhikers’ when they are physically linked to advantageous alleles are a well-described phenomenon in evolutionary biology, so the same could be expected in the evolutionary arena of cancer (Lang et al., 2013). Furthermore, genetic lesions that prime cells for apoptosis are not always selected against in cancer. On the contrary, certain oncogenes (including MYC paralogs) are strongly selected for, despite their known effect of priming for apoptosis (Mason et al., 2008; Dammert et al., 2019). While we cannot rule out the possibility that ATAD1 loss could be beneficial to tumor cells under some circumstances, our data clearly demonstrate its role as a pro-survival factor in cancer cells of diverse origins. These data also illustrate that ATAD1 is particularly important for cellular health in the context of ubiquitin proteasome system dysfunction, which can be at least partly explained by ATAD1 antagonizing BIM. Patients with metastatic prostate cancer tumors that lack ATAD1 live significantly longer, and appear to respond better to therapy, which suggests that ATAD1 is also important in the context of human tumors subjected to different stressors.

The effect of ATAD1 on apoptosis likely extends beyond PTEN-null cancers into a broader physiological context. ATAD1 has not been explicitly linked to apoptosis, but it was originally discovered in mammals via a genetic screen for factors that prevent neuronal cell death (Dai et al., 2010). Further, Atad1 phenocopies Bcl2 and Bcl2l1 in the middle cerebral artery occlusion mouse model of ischemic stroke: deletion of Atad1 or Bcl2 exacerbates, and overexpression of Atad1, Bcl2, or Bcl2l1 decreases ischemic cell death (Zhang et al., 2019; Martinou et al., 1994; Parsadanian et al., 1998; Broughton et al., 2009). We speculate that antagonism of BIM may contribute to the neuroprotective function of ATAD1 in vivo (Zhang et al., 2011).

One limitation of our study is that deletion of BIM does not completely rescue the effects of ATAD1. Even though we demonstrate that BIM is an ATAD1 substrate and that this interaction is important for the pro-survival effects of ATAD1 (such as the synthetic lethality of ATAD1 and MARCH5), there must be other ATAD1 substrates that contribute to the proteasome inhibition phenotype of ATAD1-null cells. We speculate that a multitude of ATAD1 substrates accumulate on the OMM during proteasome inhibition, and deletion of a single one (e.g. BIM) is insufficient to counteract the summative stress. Further clarity on the substrate repertoire of ATAD1 will be an important direction for future research. Future work should also clarify whether a tumor’s tissue of origin influences the dependencies generated by ATAD1 deficiency, although our use of multiple cell lines from different tumor types suggests a phenotype with reasonably high penetrance.

Overall, these data show that cells lacking ATAD1 have an increased dependency on the ubiquitin proteasome system. We therefore propose a model in which mitochondrial TA proteins have (at least) two fates: extraction by ATAD1, and ubiquitination and proteasomal degradation (Figure 4G). This model is strongly supported by the finding that ATAD1 becomes important for cellular viability only in the context of a dysfunctional UPS, such as upon MARCH5 deletion or pharmacological inhibition of the proteasome. That caspase inhibition completely rescues the absence of ATAD1 in proteasome inhibitor treated cells argues that ATAD1 is important in this context specifically for preventing apoptosis, as opposed to a general loss of cell fitness. Proteins extracted by ATAD1 may or may not be subsequently degraded by the proteasome, but ATAD1 is beneficial to the cell even when – and especially when – the proteasome is inhibited.

That ATAD1 loss sensitizes to proteasome dysfunction could have therapeutic implications for hundreds of thousands of cancer patients with Del(10q23) tumors, especially considering that drugs targeting the proteasome are already approved for the treatment of cancer. Previous trials of proteasome inhibitors in unselected patients with prostate cancer have shown activity in a subset of patients, consistent with the possibility that this subset was enriched for patients with ATAD1-null tumors (Papandreou et al., 2004; Naik et al., 2018; Morris et al., 2007). A retrospective analysis of ATAD1 status in tumors of ‘responders’ and ‘non-responders’ from these trials would be a valuable first step toward the clinical translation of our findings. We predict that pharmacological inhibitors of MARCH5 could achieve an even better therapeutic window than proteasome inhibitors in treating tumors with ATAD1 deletion, and would be an exciting area for drug development. In sum, our work uncovers a new connection between mitochondrial protein homeostasis and cell death, and has the potential for clinical impact for patients with PTEN/ATAD1 co-deleted tumors.

Materials and methods

Lead contact

Request a detailed protocol

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jared Rutter (rutter@biochem.utah.edu).

Materials availability

Request a detailed protocol

All unique/stable reagents generated within this study are available from the lead contact upon request without restriction.

Data and code availability

Request a detailed protocol

The CRISPR screening datasets generated during this study are available in the supplemental materials. The human mCRPC survival data are available in supplemental materials. The uncropped source data files for every western blot image are included in the ‘source data’ files.

Experimental model and subject details

ATAD1 knockout cell lines

Request a detailed protocol

Jurkat E6.1 human T-ALL cells (ATCC TIB-152) were grown in RPMI1640 with 10% FBS and 100 U/mL Pen/Strep (Thermo Fisher). Cells were electroporated using Lonza SE Cell Line 4D-Nucleofector X Kit L according to the manufacturer’s specifications and protocol optimized for Jurkat E6.1 cells. Px458-derived plasmids encoding sgRNA targeting ATAD1 were transiently expressed in Jurkat cells via electroporation. One of two sgRNAs were used, targeting either exon 2 (sense oligo: 5’-CCGACTCAAAGGACGAGAAA-3’) or exon 5 (sense oligo: 5’-CGGTCAGTGTCGAAGGCTGA-3’). Three days later, GFP-positive cells were sorted (BD FACSAria) and plated as single cells in 96-well plates. Clonal cell lines were grown, harvested, and evaluated for ATAD1 deletion via immunoblot using a knockout-validated monoclonal antibody (NeuroMab).

PC3 cells were transduced with lentivirus encoding LentiCRISPRv2-GFP (LCv2G) with non-targeting sgRNA (sgNT, which contains a 15 nt sgRNA sequence, 5’-GAGACGGACGTCTCT-3’, that does not precede any 5’-NGG-3’ sites in the human genome. This was determined by using GAGACGGACGTCTCTNGG as input for ncbi BLAST, and filtering results to 100% query coverage, 100% identity) or LCv2G with sgATAD1 (targeting exon 5: 5’-CGGTCAGTGTCGAAGGCTGA-3’). Three days after transduction, GFP-positive cells were sorted (BD FACSAria) and maintained as a polyclonal population. Editing was confirmed by immunoblot as above.

ATAD1 re-expression in Del(10q23) cell lines

Request a detailed protocol

H4 and PC3 cells were transduced with retrovirus (pQCXIP transfer plasmid) encoding ATAD1 with C-terminal FLAG and HA tags. Two days after transduction, cells were selected with 1 µg/mL puromycin for 4 days. RPMI7951, HGC27, and SW1088 cells were transduced with lentivirus (pLenti-Blast transfer plasmid) encoding ATAD1-FLAG, and selected with 8 µg/mL blasticidin for 6 days. Cells were grown in media containing the selective antibiotic upon thawing stocks, but no experiments were conducted using media that contained selective antibiotics.

Method details

Immunohistochemistry

Request a detailed protocol
ATAD1 (using NeuroMab #75-157 mouse monoclonal antibody)
Request a detailed protocol

The ATAD1 immunohistochemical staining was performed on 4 µm thick sections of formalin-fixed, paraffin-embedded tissues. Sections were air-dried and then melted in a 60°C oven for 30 min. Slides were loaded onto the Leica Bond III automated staining instrument (Leica Biosystems, Buffalo Grove, IL) and de-paraffinized with the Bond Dewax solution. The antigen retrieval performed was done with Bond Epitope Retrieval Buffer 2 (ER2, pH 8.0) for 20 min at 95°C. The ATAD1 primary antibody concentration of 1:400 was applied at an incubation time of 30 min at room temperature. Positive signal was visualized using the Bond Polymer Refine Detection kit-DAB, which is a goat anti-mouse/anti-rabbit secondary HRP/polymer detection system, utilizing DAB (3,3’ diaminobenzidine) as the chromogen. Tissue sections were counterstained with hematoxylin for 10 min. The slides were removed from the immunostainer and placed in a dH2O/DAWN mixture. The sections were gently washed in a mixture of deionized water and DAWN solution to remove any unbound reagent. The slides were gently rinsed in deionized water until all of wash mixture was removed. The slides were de-hydrated in graded ethanols, cleared in xylene and then coverslipped.

PTEN (using rabbit anti-human monoclonal antibody): clone 138G6, catalog #9559L, Cell Signaling, Danvers, MA
Request a detailed protocol

The PTEN immunohistochemical staining was performed on 4 µm thick sections of formalin-fixed, paraffin-embedded tissues. Sections were air-dried and then melted in a 60°C oven for 30 min. Slides were loaded onto the Ventana BenchMark Ultra automated staining instrument (Ventana Medical Systems, Tucson, AZ), de-paraffinized with the EZ Prep solution. The antigen retrieval performed was done with a citrate buffer (pH 6.0) in a pressure cooker (BioCare Medical, Concord, CA) for 4 min at 100°C then cooled in hot buffer for 30 min. The PTEN primary antibody concentration of 1:50 was applied at an incubation time of 2 hr at room temperature. The Ventana Amplification kit was applied to increase the antibody signal. Positive signal was visualized using the UltraView DAB detection kit, which is a goat anti-mouse/anti-rabbit secondary HRP/polymer detection system, utilizing DAB as the chromogen. Tissue sections were counterstained with hematoxylin for 16 min. The slides were removed from the immunostainer and placed in a dH2O/DAWN mixture. The sections were gently washed in a mixture of deionized water and DAWN solution to remove any unbound reagent and coverslip oil applied by the automated instrument. The slides were gently rinsed in deionized water until all of wash mixture was removed. The slides were de-hydrated in graded ethanols, cleared in xylene, and then coverslipped.

Cell culture

Request a detailed protocol

Jurkat cells were cultured in RPMI1640 with 10% FBS (Sigma) and 100 U/mL Pen/Strep. Cells were counted regularly and typically split at a concentration of approximately 1–1.5 × 106 cells/mL, but always before reaching a concentration of 3×106 cells/mL. Jurkat cells transduced with tet-inducible vectors were cultured in RPMI1640 with 10% ‘Tet System Approved FBS’ (Takara) instead of standard FBS. Adherent cell lines were maintained in subconfluent cultures in the following media: RPMI1640 (PC3), DMEM (H4 and SW1088), EMEM (RPMI7951 and HGC27), all with 10% FBS and 100 U/mL Pen/Strep. Cells were periodically tested for mycoplasma contamination using a MycoAlert kit and were negative.

Cloning

All cloning was conducted via traditional PCR/restriction enzyme ‘cut and paste’ methods and verified by Sanger sequencing.

ATAD1 constructs

Request a detailed protocol

Retroviral plasmids encoding ATAD1-FLAG/HA and ATAD1E193Q-FLAG/HA were published previously (Chen et al., 2014). Lentiviral vectors were made, using the pLenti-BLAST backbone, by PCR-amplifying the ATAD1 CDS from the above retroviral vectors, but truncating the construct by replacing the HA tag with a stop codon, and ligating between SalI and XbaI sites.

GFP-BIM constructs

Request a detailed protocol

The pLVXTet-One vector was purchased from Takara. The coding sequence for EGFP was PCR-amplified and ligated into the MCS using AgeI/BamHI sites. A fusion of EGFP-BIMEL was generated using SOEing PCR and ligated using AgeI/BamHI sites. EGFP-BIMEL was also ligated into pEGFP-C3 for transient transfection.

A gene fragment encoding BIMEL∆BH3 was synthesized by GeneWiz and subcloned into the pLVXTet-One vector described above to make an N-terminal GFP fusion.

CellTiterGlo viability assay

Request a detailed protocol

Viability was determined by CellTiterGlo (Promega) according to the manufacturer’s recommendation, with some modifications. Cells were plated at a density of 5×103 cells/well (adherent cell lines) or 2–4 × 104 cells/well (Jurkat) in 100 µL in 96-well plates with white walls and clear bottoms (Corning #3610). CellTiterGlo reagent was reconstituted, diluted 1:4 using sterile PBS, and stored at –20°C in 10 mL aliquots. The outer wells of the 96-well plates were filled with media but not with cells, due to concerns of edge effects. Luminescence was measured using a Biotek Synergy Neo2 microplate reader. Luminescence values were normalized on each plate to untreated cells on the same plate, and expressed as percent. Viability experiments were conducted with multiple biological replicates and repeated with independent experiments.

Incucyte

Request a detailed protocol

Jurkat cells stably transduced with TetON(GFP-BIMEL) were seeded at a density of 103 cells/well in clear-bottom, black 96-well plates (Corning) with different concentrations of doxycycline. Cells were imaged with an Incucyte SX5 system and monitored by phase contrast microscopy, with five images taken per well, every 4 hr, for approximately 4 days. Confluence was normalized to t=0 and is expressed as fold-change. Three replicate wells were used for each condition, and three independent experiments were conducted.

Spinfection

Request a detailed protocol

Jurkat cells were routinely spinfected in 12-well plates, with 2–5 × 106 cells per mL in 1 mL containing 10 µg/mL polybrene. Centrifugation was conducted at 30°C and 1100 × g for 60 min.

CRISPR-based genetic interaction experiments

Request a detailed protocol

Jurkat cells (ATAD1∆ or WT) were transduced with LentiCRISPSRv2-GFP encoding a non-targeting sgRNA (see above) or sgRNA targeting BCL2L11 (encoding BIM; gRNA: 5’-GTTGTGGCTCTGTCTGTAGGG-3’) and sorted by FACS. For MCL1 overexpression experiments, Jurkat cells transduced with LentiCRISPRv2GFP-sgNT were subsequently transduced with viral particles packaged with pLenti-GFP or pLenti-Myc-MCL1, which encodes human MCL1 with an N-terminal Myc tag, and selected with 1 µg/mL puromycin.

Viral particles were made using the LRCherry2.1 transfer plasmid, which encodes U6-sgRNA and mCherry. Cells were spinfected using 10 µg/mL polybrene and viral supernatant. The same number of cells was used for each transduction. One day after spinfection (day 1), cells were resuspended in fresh RPMI media and cultured until day 3, when they were split or seeded into 96-well plates for subsequent analysis by CellTiterGlo (Promega). Viability was calculated by dividing CellTiterGlo values (day 4 or day 7) for a given cell line transduced with sgMARCH5 (5’-GCACTGAGGACATGCCACTC-3’) or sgPCNA (5’-CTACCGCTGCGACCGCAACC-3’) by the values for the same cell line on the same plate transduced with sgAAVS1 (5’-ACTGTTGACGGCGGCGATGT-3’; Girish and Sheltzer, 2020). Cell pellets were collected on day 4 for western blot.

Crystal violet staining

Request a detailed protocol

Cells cultured in 12- or 6-well plates were washed twice with PBS then fixed with 4% paraformaldehyde (Sigma-Aldrich) for 30 min at room temperature. Wells were washed with ddH2O three times, then stained with 0.1% (w/v) crystal violet solution in 20% methanol for 30 min at room temperature. Wells were again washed with ddH2O three times, inverted to dry, and plates were photographed against a white background using an iPhone X. For quantification, glacial acetic acid was added to each well to elute the dye, and plates were incubated at room temperature on a rotary shaker for 30 min. Absorbance was measured at 590 nm using a Biotek Synergy Neo2 microplate reader, and values were normalized to those from untreated cells of the same genotype on each plate.

SDS-PAGE and immunoblotting

Request a detailed protocol

Whole cell lysates were prepared by scraping cells directly into RIPA buffer (or adding RIPA buffer to Jurkat cell pellets) supplemented with protease and phosphatase inhibitors (Sigma-Aldrich P8340, Roche Molecular 04906845001), incubated on ice for 30 min with vortexing every 10 min, and then spun at 16,000 × g for 10 min at 4°C to remove insoluble material. Supernatant was saved as lysate and concentrations were normalized for total protein content after measuring with a BCA (Thermo Scientific 23225). Samples were resolved by SDS-PAGE or Tris-glycine gels (Invitrogen XP04205BOX) and transferred to nitrocellulose or PVDF (extraction assay) membranes. Immunoblotting was performed using the indicated primary antibodies which are listed in the Key resources table according to the manufacturers’ recommendations, and analyzed by Licor Odyssey or Azure C500 (extraction assay). Note that the detector for the Azure C500 has several columns of pixels which appear to be non-functional. This gives the appearance of thin vertical white lines in some images. This can be readily viewed in raw data files by over-adjusting the contrast.

Co-immunoprecipitation

Request a detailed protocol

H4 cells (expressing EV or ATAD1-FLAG/HA) were transfected with GFP-BIMEL in pEGFP-C3 (GFP-BIM), 10 µg plasmid for 10 cm plate, in the presence of 20 µM zVAD-fmk. Transient expression proceeded overnight (approximately 16 hr). Cells were washed with cold PBS and lysed with HN buffer supplemented with protease inhibitor cocktail and 1% CHAPS (HNC buffer). Magnetic anti-FLAG beads (Sigma-Aldrich) were equilibrated with HNC buffer and then mixed with lysate (after removing 10% volume as input). Bead-lysate mixtures were incubated on a rotator at 4°C for 2–4 hr. Beads were washed 3× with HNC buffer, then heated at 65°C in 30 µL 1× Laemmli buffer for 10 min.

Cell counting

Request a detailed protocol

Cells were counted using Bio-Rad TC20 cell counter. At least two samples were taken from a culture any time a count was to be made and the mean was recorded. For proliferation experiments with Jurkat cells (cell counts over time), a hemocytometer was used.

Jurkat CRISPR screen

Request a detailed protocol

Jurkat cells (WT parental, ATAD1∆ #1, and ATAD1∆ #2) were transduced by spinfection with a genome-wide lentiviral sgRNA library (Addgene #1000000100; Wang et al., 2015) that also encoded Cas9 and a puromycin resistance cassette. Transduction was optimized to achieve an approximate transduction efficiency of 30%, and cells were selected with puromycin (0.5 µg/mL) for 3 days, allowed to recover without puromycin for 2 days, then maintained in a lower dose of puromycin (0.2 µg/mL) for the duration of the screen. An initial sample of cells (8×107) were collected and frozen at the endpoint of puromycin selection (6 days post-transduction). Cells were then maintained in culture for 14 cumulative population doublings (CPDs). Cells were passaged every 2 days and seeded into new flasks at a density of 2×105 cells/mL. After 14 population doublings, representative samples were collected (8×107 cells). As described elsewhere (Adelmann et al., 2019), cell pellets were processed using a QIAamp DNA Blood Maxiprep, sgRNA sequences were amplified by PCR, and amplicons were sequenced for 40 cycles by Illumina HiSeq NGS at the Whitehead Institute Genome Technology Core Facility.

Sequencing reads were aligned to the sgRNA library, given a pseudocount of 1, the counts from each sample were normalized for sequencing depth, and the relative abundance of each sgRNA was calculated as described previously (Wang et al., 2015; Kanarek et al., 2018). sgRNAs with fewer than 50 reads, and genes with fewer than 4 sgRNAs, in the initial reference dataset were omitted from downstream analyses. The log2 fold-change in abundance of each sgRNA between the final and initial reference populations was calculated and used to define a CS for each gene. The CS is the average log2 fold-change in abundance of all sgRNAs targeting a given gene. To achieve a direct comparison of gene essentiality in an ATAD1∆ clone to that in the WT control, we omitted sgRNAs that were not adequately represented (i.e. <50 reads at the initial time point) in both groups. This step enables a paired analysis of sgRNA changes in abundance, and avoids including a given sgRNA that ‘scored’ in one genetic background but whose effects cannot be assessed in another. Data were analyzed and plotted using ggplot2 with R version 4 and RStudio version 1.1.442.

HGC27 CRISPR screen

Request a detailed protocol

The HGC27 CRISPR screen was conducted using the Brunello sgRNA library, which was obtained from Addgene and amplified according to the instructions provided by the depositing lab. HGC27 cells transduced with pLentiBLAST-EV or ATAD1-FLAG were selected and propagated as described above. Cells were spinfected with viral sgRNA library, and 1 day later were treated with puromycin (0.5 µg/mL) for 2 days. The following day (day 4), cell pellets were collected for the initial time point (CPD = 0). Mock-transduced cells were included as a control and demonstrated complete death in response to puromycin. Pellets (80e6 cells) were collected at CPDs of 0 and 14. Genomic DNA was harvested as described above. Sequencing libraries were prepared by University of Utah Genomics Core. Sequencing reads were aligned and quantified using BBtools Seal. Counts were normalized for library size and a pseudocount was added to each value. CS per gene were calculated as the mean log2-transformed fold-change in sgRNA abundance between the final time point (CPD 14) and the initial time point post-infection and antibiotic selection (CPD 0). Selectively essential genes were ranked by dCS:

dCS = (CSEV−CSATAD1+)

BH3 profiling

Request a detailed protocol

BH3 profiling was conducted using a FACS-based method to directly monitor cytochrome C release/retention in cells, as described previously (Ryan and Letai, 2013).

Confocal microscopy

Request a detailed protocol

SW1088 cells transduced with EV or ATAD1-FLAG and TetON(GFP-BIMEL∆BH3) were seeded at a density of 3.5×104 cells per dish, in 35 mm Fluorodish plates (World Precision Instruments). Approximately 16 hr later, media was removed and replaced with media containing 100 ng/mL doxycycline. After 24 hr, cells were treated with 20 nM MitoTracker Red for 15 min and then imaged on a Zeiss LSM 880 confocal laser scanning microscope for 45 min in 5% CO2 at 37°C. Imaging on the Zeiss LSM 880 confocal laser scanning microscope was performed with a Plan-Apochromat 63×/1.40 Oil DIC f/ELYR objective. Alternatively, cells were treated with 100 nM bortezomib for 90 min prior to imaging, were stained with MitoTracker Red as described above, and imaged for 30 min. Doxycycline concentrations were maintained throughout the staining and imaging process. All images were Airyscan processed using the Zeiss Zen Desk software.

Microscopy was conducted by an investigator (C Cunningham) who was blinded to genotype (EV vs. ATAD1) and treatment (presence or absence of bortezomib). Experiments were repeated for three independent replicates (both with and without bortezomib) and two additional replicates (without bortezomib only). At least 30 images (representing approximately 40–60 cells) were taken per condition, per replicate. GFP-positive, MitoTracker Red-negative puncta were counted using FIJI with the multi-point tool and were graphed using GraphPad Prism 9 for MacOS.

Co-localization of GFP-BIMEL∆BH3 and mito-mCherry was analyzed by Coloc2 package (FIJI). Regions of interest were defined by selecting entire cells but excluding nuclei using the GFP channel. All images were identically processed by background subtraction and smoothening. Each data point represents the cytoplasmic region of interest for one cell.

Mouse xenografts

Request a detailed protocol

SW1088 cells (transduced with EV or ATAD1-FLAG) were grown under normal culture conditions, as described above. Cells (3×106) were mixed 1:1 with Matrigel (Corning) and injected into one flank per mouse. Mice were male NOD/SCID aged 13–15 weeks. Tumor volumes were monitored biweekly using a Biopticon TumorImager. Animal experiments were conducted in accordance with The University of Utah IACUC.

PC3 cells (transduced with LentiCRISPRv2-sgNT or sgATAD1) were grown as described above. Cells (1.8×106) were mixed 1:1 with Matrigel (Corning) and injected into one flank per mouse (12-week-old, male, NRG). Once tumors had established, mice were randomized into bortezomib or vehicle groups and treatment occurred by tail-vein injection twice weekly for 4 weeks. At the conclusion of the experiment, mice were sacrificed within 24 hr of receiving an IV injection. Tumors were harvested and snap-frozen on liquid nitrogen. Tumor fragments were homogenized in RIPA buffer using ceramic beads on a Omni Bead Ruptor 24 Bead Mill Homogenizer (2 cycles of 45 s at 6 m/s, 4°C). Homogenates were centrifuged (16,000 RCF, 10 min, 4°C) and supernatants were recovered, then used for downstream analysis by immunoblot. Data were analyzed by mixed effects model with Tukey’s multiple comparisons. Animal experiments were conducted in accordance with The University of Utah IACUC.

Patient data

Request a detailed protocol

Outcome data from patients with mCRPC were downloaded from TCGA via cBioPortal. Patients were stratified into three groups based on status of ATAD1 and PTEN (unaltered vs. null). Raw data are available as a table in Source data 3.

Bacterial transformation

Request a detailed protocol

For cloning, Escherichia coli DH5α competent cells (New England Biolabs) were transformed according to the manual provided by the manufacturer and grown on LB agar plates at 37°C overnight. For cloning of lentiviral and retroviral vectors, NEB Stable competent cells were used (NEB C3040I).

E. cloni cells

Request a detailed protocol

For cloning, E. cloni10G competent cells were transformed according to the manual provided by the manufacturer (Lucigen) and grown on LB agar plates at 37°C overnight.

BL21-DE3 pRIL cells

Request a detailed protocol

For protein expression, E. coli BL21(DE3) containing a pRIL plasmid and a protein expression vector were grown in terrific broth at 37°C until an OD600 of 0.6–1.0. Cultures were induced with isopropyl-1-thio-β-D-galactopyranoside (IPTG) at a final concentration of 1 mM and grown at room temperature for an additional 3–4 hr.

Production of soluble constructs

Δ1-32 Msp1 and Δ1-39ATAD1

Request a detailed protocol

The gene encoding the soluble region of Saccharomyces cerevisiae Msp1 (Δ1–32) was PCR-amplified from genomic DNA and subcloned into a pET28a derivative (Novagen) encoding an N-terminal 6×His tag followed by a TEV protease cleavage site. The soluble region of Rattus norvegicus ATAD1 (Δ1-39) was PCR-amplified from a plasmid containing ATAD1 cDNA (GE Healthcare). All insertions and deletions were performed by standard PCR techniques. Site-specific mutagenesis was carried out by QuickChange PCR. All constructs were verified by DNA sequencing.

Plasmids encoding soluble Msp1, ATAD1, or their mutants were purified as described previously (Wohlever et al., 2017). Plasmids were transformed into E. coli BL21(DE3) containing a pRIL plasmid and expressed in terrific broth at 37°C until an OD600 of 0.6–1.0, cultures were induced with 1 mM IPTG and grown at room temperature for an additional 3–4 hr. Cells were harvested by centrifugation, and resuspended in Msp1 Lysis Buffer (20 mM Tris pH 7.5, 200 mM KAc, 20 mM imidazole, 0.01 mM EDTA, 1 mM DTT) supplemented with 0.05 mg/mL lysozyme (Sigma), 1 mM phenylmethanesulfonyl fluoride (PMSF) and 500 U of universal nuclease (Pierce), and lysed by sonication. The supernatant was isolated by centrifugation for 30 min at 4°C at 18,500 × g and purified by Ni-NTA affinity chromatography (Pierce) on a gravity column. Ni-NTA resin was washed with 10 column volumes (CV) of Msp1 Lysis Buffer and then 10 CV of Wash Buffer (Msp1 Lysis buffer with 30 mM imidazole) before elution with Lysis Buffer supplemented with 250 mM imidazole. Purification of soluble ATAD1 also included the addition of ATP to stabilize the protein. ATP was added to a final concentration of 2 mM after sonication and again after elution from the nickel resin.

The protein was further purified by size exclusion chromatography (SEC) (Superdex 200 Increase 10/300 GL, GE Healthcare) in 20 mM Tris pH 7.5, 200 mM KAc, 1 mM DTT. Peak fractions were pooled, concentrated to 5–15 mg/mL in a 30 kDa MWCO Amicon Ultra centrifugal filter (Pierce) and aliquots were flash-frozen in liquid nitrogen and stored at –80°C. Protein concentrations were determined by A280 using a calculated extinction coefficient (Expasy).

GST-SGTA and GST-calmodulin

Request a detailed protocol

GST-tagged SGTA was expressed and purified as described previously (Mateja et al., 2015). The original calmodulin plasmid was a kind gift of the Hegde lab (Shao and Hegde, 2011). Calmodulin was cloned into pGEX6p1 plasmid by standard methods. GST-SGTA and GST-calmodulin were expressed as described above for soluble Msp1 constructs. Cells were harvested by centrifugation and resuspended in SGTA Lysis Buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 0.01 mM EDTA, 1 mM DTT, 10% glycerol) supplemented with 0.05 mg/mL lysozyme (Sigma), 1 mM PMSF and 500 U of universal nuclease (Pierce), and lysed by sonication. The supernatant was isolated by centrifugation for 30 min at 4°C at 18,500 × g and purified by glutathione affinity chromatography (Thermo Fisher) on a gravity column. Resin was washed with 20 CV of SGTA Lysis Buffer and then eluted with 3 CV of SGTA Lysis Buffer supplemented with 10 mM reduced glutathione. The protein was further purified by SEC (Superdex 200 Increase 10/300 GL, GE Healthcare) in 20 mM Tris pH 7.5, 100 mM NaCl, 0.1 mM TCEP. Peak fractions were pooled, concentrated to 10 mg/mL in a 30 kDa MWCO Spin Concentrator (Pierce) and aliquots were flash-frozen in liquid nitrogen and stored at –80°C. Protein concentrations were determined by A280 using a calculated extinction coefficient (Expasy).

Production of membrane proteins

BIM and Fis1

Request a detailed protocol

Homo sapiens BimL, S. cerevisiae Fis1 TMD ±5 flanking amino acids (residues 126–155), H. sapiens Bik, or H. sapiens Puma was cloned in place of the Sec22 TMD in the SumoTMD construct described previously (Wang et al., 2010; Wohlever et al., 2017). These constructs have N-terminal His6 and 3× Flag tags and a C-terminal opsin glycosylation site (11 residues). A 3C protease site was added immediately after the His tag by standard PCR methods. The resulting constructs are His6-3C-3xFlag-Sumo-thrombin-BimL-Opsin and His6-3C-3xFlag-Sumo-thrombin-Fis1(126-155)-Opsin, His6-3C-3xFlag-Sumo-thrombin-Bik-Opsin, and His6-3C-3xFlag-Sumo-thrombin-Puma-Opsin.

Expression plasmids for SumoTMD were transformed into E. coli BL21(DE3) containing a pRIL plasmid and expressed in terrific broth at 37°C until an OD600 of 0.6–0.8, cultures were induced with 0.4 mM IPTG and grown at 20°C for an additional 3–4 hr. Cells were harvested by centrifugation, and resuspended in SumoTMD Lysis Buffer (50 mM Tris pH 7.5, 300 mM NaCl, 10 mM MgCl2, 10 mM imidazole, 10% glycerol) supplemented with 0.05 mg/mL lysozyme (Sigma), 1 mM PMSF and 500 U of universal nuclease (Pierce), and lysed by sonication. Membrane proteins were solubilized by addition of n-dodecyl-β-D-maltoside (DDM) to a final concentration of 1% and rocked at 4°C for 30’. Lysate was cleared by centrifugation for at 4°C for 1 hr at 35,000 × g and purified by Ni-NTA affinity chromatography.

Ni-NTA resin was washed with 10 CV of SumoTMD Wash Buffer 1 (50 mM Tris pH 7.5, 500 mM NaCl, 10 mM MgCl2, 10 mM imidazole, 5 mM β-mercaptoethanol (BME), 10% glycerol, 0.1% DDM). Resin was then washed with 10 CV of SumoTMD Wash Buffer 2 (same as Wash Buffer 1 except with 300 mM NaCl and 25 mM imidazole) and 10 CV of SumoTMD Wash Buffer 3 (same as Wash Buffer 1 with 150 mM NaCl and 50 mM imidazole) and then eluted with 3 CV of SumoTMD Elution Buffer (same as Wash Buffer 3 except with 250 mM imidazole).

The protein was further purified by SEC (Superdex 200 Increase 10/300 GL, GE Healthcare) in 50 mM Tris pH 7.5, 150 mM NaCl, 10 mM MgCl2, 5 mM BME, 10% glycerol, 0.1% DDM. Peak fractions were pooled and concentrated in a 30 kDa MWCO spin concentrator (Pierce). Sample was then incubated with 3C Protease at a 1:100 ratio at 4°C overnight to remove the His tag. The following day, the sample was run over Ni-NTA resin equilibrated in Lysis Buffer to remove 3C protease, His tag, and uncleaved proteins. Flow through was collected, aliquoted, and flash-frozen in liquid nitrogen and stored at –80°C. Protein concentrations were determined by A280 using a calculated extinction coefficient (Expasy).

Msp1

Request a detailed protocol

Full-length S. cerevisiae Msp1 was PCR-amplified from genomic DNA, subcloned into a pET21b derivative with a C-terminal 6×His tag, and expressed as described above for the soluble constructs. Cells were lysed by sonication and the insoluble fraction was harvested by centrifugation for 1 hr at 4° C at 140,000 × g. After resolubilizing for 16 hr in Msp1 Lysis Buffer containing 1% DDM (Bioworld), the detergent-soluble supernatant was isolated by centrifugation for 45 min at 142,000 × g and purified by Ni-NTA affinity chromatrography and SEC as described above for the soluble constructs, except that all buffers contained 0.05% DDM. Peak fractions were concentrated in 100 kDa MWCO Amicon Ultra centrifugal filter (Millipore). Protein concentrations were determined by A280 using a calculated extinction coefficient (Expasy) and aliquots were flash-frozen in liquid nitrogen.

Reconstitution of Msp1 activity in proteoliposomes

Liposome preparation

Request a detailed protocol

Liposomes mimicking the lipid composition of the yeast OMM were prepared as described (Kale et al., 2014). Briefly, a 25 mg lipid film was prepared by mixing chloroform stocks of chicken egg phosphatidyl choline (Avanti 840051C), chicken egg phosphatidyl ethanolamine (Avanti 840021C), bovine liver phosphatidyl inositol (Avanti 840042C), synthetic DOPS (Avanti 840035C), and synthetic TOCL (Avanti 710335C) at a 48:28:10:10:4 molar ratio with 1 mg of DTT. Nickel liposomes were made as described above, except, 1,2-dioleoyl-sn-glycero-3-[N-((5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] Nickel salt (Avanti 790404) was used at a molar ratio of 2% and DOPS was dropped from 10% to 8%.

Chloroform was evaporated under a gentle steam of nitrogen and then left on a vacuum (<1 mTorr) overnight. Lipid film was resuspended in Liposome Buffer (50 mM HEPES KOH pH 7.5, 15% glycerol, 1 mM DTT) to a final concentration of 20 mg/mL and then subjected to five freeze-thaw cycles with liquid nitrogen. Liposomes were extruded 15 times through a 200 nm filter at 60°C, distributed into single-use aliquots, and flash-frozen in liquid nitrogen.

Proteoliposome preparation

Request a detailed protocol

For extraction assays with full-length Msp1, proteoliposomes were prepared by mixing 1 µM Msp1, 1 µM TA protein (SumoTMD), and 2 mg/mL of mitochondrial liposomes in Reconstitution Buffer (50 mM HEPES KOH pH 7.5, 200 mM potassium acetate, 7 mM magnesium acetate, 2 mM DTT, 10% sucrose, 0.01% sodium azide, and 0.1% deoxy big chaps). For extraction assays with soluble Msp1/ATAD1, proteoliposomes were prepared by mixing 1 µM TA protein (SumoTMD), and 2 mg/mL of Nickel liposomes in Reconstitution Buffer. Detergent was removed by adding 25 mg of biobeads and rotating the samples for 16 hr at 4°C. After removing biobeads, unincorporated TA protein was pre-cleared by incubating the reconstituted material with excess (5 µM) GST-SGTA and GST-calmodulin and passing over a glutathione spin column (Pierce #16103); the flow through was collected and used immediately for dislocation assays.

Extraction assay

Request a detailed protocol

Extraction assays contained 60 µL of pre-cleared proteoliposomes, 5 µM GST-SGTA, 5 µM calmodulin, and 2 mM ATP and the final volume was adjusted to 200 µL with Extraction Buffer (50 mM HEPES KOH pH 7.5, 200 mM potassium acetate, 7 mM magnesium acetate, 2 mM DTT, 0.1 µM calcium chloride). Samples were incubated at 30°C for 35 min and then loaded onto a glutathione spin column. Columns were washed 4× with Extraction Buffer and eluted with the same buffer supplemented with 20 mM glutathione pH 8.5. Samples were loaded onto stain-free gels, imaged, and then transferred to a PVDF membrane and blotted as indicated in the Key resources table. To account for variability in reconstitution efficiency and western blotting, a new reconstitution and dislocation assay with WT Msp1 was done in parallel with each mutant Msp1. Figures are representative of N>3 separate reconstitutions. Note that the ‘input’ lane is diluted 5× relative to the ‘elution’ lane.

Quantification and statistical analysis

Request a detailed protocol

To account for variability in reconstitution efficiency and western blotting, a new reconstitution and dislocation assay with WT Msp1 was done in parallel with each Msp1 mutant. Figures are representative of N>3 separate reconstitutions. Dislocation efficiency was quantified by comparing the amount TA protein in the ‘elution’ lane with the amount of substrate in the ‘input’ lane.

Appendix 1

Appendix 1—key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Cell line (human)HEK293T cellsATCC#CRL-11268, RRID:CVCL_1926
Cell line (human)Jurkat E6.1ATCCTIB-152
Cell line (human)H4ATCCHTB-148
Cell line (human)RPMI-7951ATCCHTB-66
Cell line (human)SW1088ATCCHTB-12
Cell line (human)PC3ATCCCRL-1435
Cell line (human)HGC27HGC2794042256
AntibodyAnti-Flag
Mouse mAB		Sigma-Aldrich#F7425, RRID:AB_4396871:5000
AntibodyAnti-V5
Mouse mAB		Abcam#ab9116, RRID:AB_3070241:5000
AntibodyAnti-GFP
Rabbit mAB		Cell Signaling#2956S1:5000
AntibodyAnti-ATAD1
Mouse mAB		NeuroMab75–1571:1000
AntibodyAnti-PTEN
Rabbit mAB		CST#91881:1000
AntibodyAnti-beta actin
Rabbit mAB		CST#49701:20,000
AntibodyAnti-alpha tubulin
Mouse mAB		CST#38731:20,000
AntibodyAnti-MCL1
Rabbit mAB		CST942961:1000
AntibodyAnti-BCLXL
Rabbit mAB		CST27641:1000
AntibodyAnti-pBIM(Ser69)
Rabbit mAB		CST45851:1000
AntibodyAnti-pBIM(Ser77)
Rabbit mAB		CST124331:1000
AntibodyAnti-pBIM(Thr112)
Rabbit mAB		Thermo FisherPA5-646551:1000
AntibodyAnti-NRF1/TCF11
Rabbit mAB		CST80521:1000
AntibodyAnti-BID
Rabbit mAB		CST20021:1000
AntibodyAnti-MAVS
Rabbit mAB		CST249301:1000
AntibodyAnti-MFF
Rabbit mAB		AbcamAB1290751:1000
AntibodyAnti-FIS1
Rabbit mAB		AbcamAB1568561:1000
AntibodyAnti-BIM
Rabbit mAB		CST#29331:1000
AntibodyAnti-BAK
Rabbit mAB		CST#121051:1000
AntibodyAnti-ubiquitin
Rabbit mAB		CST#431241:1000
AntibodyAnti-ubiquitin
Mouse mAB		Abcam#ab72541:1000
AntibodyAnti-GAPDH
Mouse mAB		CST#97166S1:5000
AntibodyAnti-PARP
Rabbit mAB		CST#95321:1000
AntibodyAnti-Caspase 3
Rabbit mAB		CST#14220S1:1000
AntibodyGoat Anti-Mouse IgG (H&L) Antibody Dylight 800 ConjugatedRockland#610-145-002-0.51:10,000
AntibodyDonkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 680Invitrogen#A100431:10,000
AntibodyGoat Anti-Mouse IgG (H+L) Antibody, Alexa Fluor 680 ConjugatedInvitrogen#A21057, RRID:AB_1414361:10,000
AntibodyDonkey Anti-Rabbit IgG (H&L) Antibody Dylight 800 ConjugatedRockland#611-145-002-0.5, AB_111835421:10,000
AntibodyGoat anti-Mouse IgG (H+L), Superclonal Recombinant Secondary Antibody, HRPThermo Fisher#A28177, RRID:AB_25361631:10,000
AntibodyGoat anti-Rabbit IgG (H+L), HRPProteinTechRRID:AB_27225641:10,000
Recombinant DNA reagentpsPAX2Addgene
Recombinant DNA reagentpMD2.GAddgene
Recombinant DNA reagentpSpCas9(BB)–2A-GFP (PX458)Addgene
Recombinant DNA reagentLentiCRISPRv2GFP-sgNTAddgene
Recombinant DNA reagentPx458_sgATAD1_1This studysgRNA targeting ATAD1 in Px458 vector; see Materials and methods
Recombinant DNA reagentPx458_sgATAD1-2This studysgRNA targeting ATAD1 in Px458; see Materials and methods
Recombinant DNA reagentLRCherry2.1-sgMARCH5_10This studysgRNA targeting MARCH5 in LRCherry2.1; see Materials and methods
Recombinant DNA reagentLRCherry2.1-sgPCNAAddgene
Recombinant DNA reagentLRCherry2.1-sgAAVS1Addgene
Recombinant DNA reagentpLenti-BlastAddgene
Recombinant DNA reagentpQCXIPClontech
Recombinant DNA reagentpQCXIP-ATAD1-FLAG/HAChen et al., 2014
Recombinant DNA reagentpQCXIP-ATAD1^E193Q-FLAG/HAChen et al., 2014
Recombinant DNA reagentpQCXIP-mito-mCherryThis studyCox8-MTS upstream of mCherry, in PQCXIP
Recombinant DNA reagentpQCXIP-mRFP-SKLThis studySKL amino acids fused to C-terminus of mRFP in pQCXIP
Recombinant DNA reagentpLenti-Blast-ATAD1-FLAGThis studyATAD1 CDS with C-terminal FLAG tag cloned into pLenti-Blast
Recombinant DNA reagentpLVX-TetOne-PuroTakara
Recombinant DNA reagentpLVX-TetOne-Puro-GFPThis studyGFP CDS cloned into pLVX-TetOne-Puro
Recombinant DNA reagentpLVX-TetOne-Puro-GFP-BIMELThis studyGFP-BIMEL fusion cloned into pLVX-TetOne-Puro
Recombinant DNA reagentpLVX-TetOne-Puro-GFP-BIMEL∆BH3This studyGFP-BIMEL fusion with 3 amino acids in BH3 domain mutated, cloned into pLVX-TetOne-Puro
Recombinant DNA reagentpLenti-GFP-PuroAddgene
Recombinant DNA reagentpLenti-Myc-MCL1This studyMCL1 with N-terminal Myc tag swapped with GFP in pLenti-GFP-Puro
Recombinant DNA reagentBrunello CRISPR knockout sgRNA libraryAddgene
Recombinant DNA reagentpET21: Msp1-His (S. cerevisiae)Wohlever et al., 2017
Recombinant DNA reagentpET28: His-TEV-∆1–32-Msp1 (S. cerevisiae)Wohlever et al., 2017
Recombinant DNA reagentpET28: His-TEV-∆1-39-ATAD1 (R. norvegicus)This studyWohlever Lab; see Materials and methods
Recombinant DNA reagentpET28: His-Flag-Sumo-Sec22 TMD-OpsinWang et al., 2010
Recombinant DNA reagentpET28: His-Flag-Sumo-BimL-OpsinThis studyWohlever Lab; see Materials and methods
Recombinant DNA reagentpET28: His-Flag-Sumo-Fis1 TMD-OpsinThis studyWohlever Lab; see Materials and methods
Recombinant DNA reagentpET28: His-Flag-Sumo-Bik-OpsinThis studyWohlever Lab; see Materials and methods
Recombinant DNA reagentpET28: His-Flag-Sumo-Puma-OpsinThis studyWohlever Lab; see Materials and methods
Recombinant DNA reagentpGEX6p1: GST-SGTAMateja et al., 2015
Recombinant DNA reagentpGEX6p1: GST-CalmodulinShao and Hegde, 2011
Commercial assay or kitPierce BCAThermo23225
Commercial assay or kitCellTiterGlo Luminescent Viability AssayPromegaG7572
Chemical compound, drugDDMGoldBioDDM25
Chemical compound, drugLipofectamine 3000Thermo FisherL3000008
Chemical compound, drugLipofectamine RNAiMAXInvitrogen13778150
Chemical compound, drugMitoTracker Red CMXRosInvitrogenM7512
Chemical compound, drugLysoTracker Blue DND-22InvitrogenL7525
Chemical compound, drugMitoTracker Deep Red FMInvitrogenM22426
Chemical compound, drugCrystal VioletSigmaC0775
Chemical compound, drugRIPA BufferCell Signaling9806
Chemical compound, drugSE Cell Line 4D-Nucleofector X Kit LLonzaV4XC-1012
Chemical compound, drugAdenosine TriphosphateAcros OrganicsAC10280-0100
Chemical compound, drugBovine liver phosphatidyl inositolAvanti840042C-10mg
Chemical compound, drugSynthetic DOPSAvanti840035C-10mg
Chemical compound, drugSynthetic DOGS-Ni-NTAAvanti790404C-5mg
Chemical compound, drugChicken egg phosphatidyl ethanolamineAvanti840021C-25mg
Chemical compound, drugChicken egg phosphatidyl cholineAvanti840051C-200mg
Chemical compound, drugSynthetic TOCLAvanti710335C-25mg
Chemical compound, drugBortezomibEMD Millipore5043140001
Chemical compound, drugCarfilzomibSelleck ChemS2853
Chemical compound, drugMarizomibSelleck ChemS7504
Chemical compound, drugzVAD-FMKSigma-AldrichV116
Software, algorithmmetapMichael Dewey, 2020
Software, algorithmRR Core Team
Software, algorithmGgplot2Wickham, 2009
OtherSuperSep PhosTag precast gels, 12.5% acWako/Fujifilm195-17991

Data availability

All data and source data generated or analyzed are included as supplementary files. CRISPR screening data and human mCRPC survival data are provided as supplementary files.

References

    1. Nakai M
    2. Endo T
    3. Hase T
    4. Matsubara H
    (1993)
    Intramitochondrial protein sorting. Isolation and characterization of the yeast msp1 gene which belongs to a novel family of putative ATPases
    The Journal of Biological Chemistry 268:24262–24269.
    1. Parsadanian AS
    2. Cheng Y
    3. Keller-Peck CR
    4. Holtzman DM
    5. Snider WD
    (1998)
    Bcl-xl is an antiapoptotic regulator for postnatal CNS neurons
    The Journal of Neuroscience 18:1009–1019.

Article and author information

Author details

  1. Jacob M Winter

    Department of Biochemistry, University of Utah, Salt Lake City, United States
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Visualization, Methodology, Writing – original draft, Writing – review and editing
    Competing interests
    has filed a patent related to this work. Reference: WO2021/257910
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7152-183X

  2. Heidi L Fresenius

    Department of Chemistry & Biochemistry, University of Toledo, Toledo, United States
    Contribution
    Formal analysis, Investigation, Methodology
    Competing interests
    No competing interests declared

  3. Corey N Cunningham

    Department of Biochemistry, University of Utah, Salt Lake City, United States
    Contribution
    Formal analysis, Investigation
    Competing interests
    No competing interests declared

  4. Peng Wei

    Department of Biochemistry, University of Utah, Salt Lake City, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  5. Heather R Keys

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Contribution
    Formal analysis, Investigation, Methodology
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1371-2288

  6. Jordan Berg

    Department of Biochemistry, University of Utah, Salt Lake City, United States
    Contribution
    Formal analysis, Investigation
    Competing interests
    No competing interests declared

  7. Alex Bott

    Department of Biochemistry, University of Utah, Salt Lake City, United States
    Contribution
    Formal analysis, Investigation
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2273-8922

  8. Tarun Yadav

    Department of Biochemistry, University of Utah, Salt Lake City, United States
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  9. Jeremy Ryan

    Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3327-1283

  10. Deepika Sirohi

    University of Utah and ARUP Laboratories, Salt Lake City, United States
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  11. Sheryl R Tripp

    University of Utah and ARUP Laboratories, Salt Lake City, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  12. Paige Barta

    Department of Biochemistry, University of Utah, Salt Lake City, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  13. Neeraj Agarwal

    Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
    Contribution
    Resources, Data curation
    Competing interests
    No competing interests declared

  14. Anthony Letai

    Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Contribution
    Resources
    Competing interests
    No competing interests declared

  15. David M Sabatini

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    Contribution
    Resources
    Competing interests
    No competing interests declared

  16. Matthew L Wohlever

    Department of Chemistry & Biochemistry, University of Toledo, Toledo, United States
    Contribution
    Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9406-3410

  17. Jared Rutter

    1. Department of Biochemistry, University of Utah, Salt Lake City, United States
    2. Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
    3. Howard Hughes Medical Institute, Salt Lake City, United States
    Contribution
    Conceptualization, Resources, Supervision, Funding acquisition, Writing – review and editing
    For correspondence
    rutter@biochem.utah.edu
    Competing interests
    has filed a patent related to this work. Reference: WO2021/257910
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2710-9765

Funding

National Institutes of Health (1F30CA243440)

  • Jacob M Winter

National Institutes of Health (1T32DK11096601)

  • Jordan Berg

National Institutes of Health (1F99CA253744)

  • Jordan Berg

National Institutes of Health (5T32DK091317)

  • Corey N Cunningham

National Institutes of Health (1F32GM140525)

  • Corey N Cunningham

National Institutes of Health (K00CA212445)

  • Alex Bott

National Institutes of Health (R35GM137904)

  • Matthew L Wohlever

National Institutes of Health (CA228346)

  • Jared Rutter

National Institutes of Health (R35GM131854)

  • Jared Rutter

Howard Hughes Medical Institute

  • Jared Rutter

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

The authors acknowledge University of Utah Core Facilities, particularly James Marvin, PhD, and the Flow Cytometry Core, David Lum, PhD, and the Preclinical Research Resource, the DNA/Peptide Synthesis Core, Brian Dalley, PhD, and the High-Throughput Genomics Core, as well as the Whitehead Institute Genome Technology Core Facility. We thank Keren Hilgendorf for equipment. We thank Derick Torres for technical lab support. We thank Florian Muller for helpful conversations and insight. We thank Jeff Morgan, Sarah Fogarty, and other members of the Rutter lab for helpful discussions and comments on the manuscript.

Ethics

All of the animals were handled according to approved institutional animal care and use committee (IACUC protocol # 18-11004) protocols of the University of Utah. Every effort was made to minimize suffering.

Copyright

© 2022, Winter et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,973
    views
  • 369
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jacob M Winter
  2. Heidi L Fresenius
  3. Corey N Cunningham
  4. Peng Wei
  5. Heather R Keys
  6. Jordan Berg
  7. Alex Bott
  8. Tarun Yadav
  9. Jeremy Ryan
  10. Deepika Sirohi
  11. Sheryl R Tripp
  12. Paige Barta
  13. Neeraj Agarwal
  14. Anthony Letai
  15. David M Sabatini
  16. Matthew L Wohlever
  17. Jared Rutter
(2022)
Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction
eLife 11:e82860.
https://doi.org/10.7554/eLife.82860

Share this article

https://doi.org/10.7554/eLife.82860

Categories and tags

Research organisms

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease

    Malaria parasites require a divergent heme oxygenase for apicoplast gene expression and biogenesis

    Amanda Mixon Blackwell, Yasaman Jami-Alahmadi ... Paul A Sigala
    Research Article

    Malaria parasites have evolved unusual metabolic adaptations that specialize them for growth within heme-rich human erythrocytes. During blood-stage infection, Plasmodium falciparum parasites internalize and digest abundant host hemoglobin within the digestive vacuole. This massive catabolic process generates copious free heme, most of which is biomineralized into inert hemozoin. Parasites also express a divergent heme oxygenase (HO)-like protein (PfHO) that lacks key active-site residues and has lost canonical HO activity. The cellular role of this unusual protein that underpins its retention by parasites has been unknown. To unravel PfHO function, we first determined a 2.8 Å-resolution X-ray structure that revealed a highly α-helical fold indicative of distant HO homology. Localization studies unveiled PfHO targeting to the apicoplast organelle, where it is imported and undergoes N-terminal processing but retains most of the electropositive transit peptide. We observed that conditional knockdown of PfHO was lethal to parasites, which died from defective apicoplast biogenesis and impaired isoprenoid-precursor synthesis. Complementation and molecular-interaction studies revealed an essential role for the electropositive N-terminus of PfHO, which selectively associates with the apicoplast genome and enzymes involved in nucleic acid metabolism and gene expression. PfHO knockdown resulted in a specific deficiency in levels of apicoplast-encoded RNA but not DNA. These studies reveal an essential function for PfHO in apicoplast maintenance and suggest that Plasmodium repurposed the conserved HO scaffold from its canonical heme-degrading function in the ancestral chloroplast to fulfill a critical adaptive role in organelle gene expression.

    1. Biochemistry and Chemical Biology
    2. Cell Biology

    Endogenous oligomer formation underlies DVL2 condensates and promotes Wnt/β-catenin signaling

    Senem Ntourmas, Martin Sachs ... Dominic B Bernkopf
    Research Article

    Activation of the Wnt/β-catenin pathway crucially depends on the polymerization of dishevelled 2 (DVL2) into biomolecular condensates. However, given the low affinity of known DVL2 self-interaction sites and its low cellular concentration, it is unclear how polymers can form. Here, we detect oligomeric DVL2 complexes at endogenous protein levels in human cell lines, using a biochemical ultracentrifugation assay. We identify a low-complexity region (LCR4) in the C-terminus whose deletion and fusion decreased and increased the complexes, respectively. Notably, LCR4-induced complexes correlated with the formation of microscopically visible multimeric condensates. Adjacent to LCR4, we mapped a conserved domain (CD2) promoting condensates only. Molecularly, LCR4 and CD2 mediated DVL2 self-interaction via aggregating residues and phenylalanine stickers, respectively. Point mutations inactivating these interaction sites impaired Wnt pathway activation by DVL2. Our study discovers DVL2 complexes with functional importance for Wnt/β-catenin signaling. Moreover, we provide evidence that DVL2 condensates form in two steps by pre-oligomerization via high-affinity interaction sites, such as LCR4, and subsequent condensation via low-affinity interaction sites, such as CD2.

    1. Biochemistry and Chemical Biology

    Identification of suitable target/E3 ligase pairs for PROTAC development using a rapamycin-induced proximity assay (RiPA)

    Bikash Adhikari, Katharina Schneider ... Elmar Wolf
    Research Article

    The development of proteolysis targeting chimeras (PROTACs), which induce the degradation of target proteins by bringing them into proximity with cellular E3 ubiquitin ligases, has revolutionized drug development. While the human genome encodes more than 600 different E3 ligases, current PROTACs use only a handful of them, drastically limiting their full potential. Furthermore, many PROTAC development campaigns fail because the selected E3 ligase candidates are unable to induce degradation of the particular target of interest. As more and more ligands for novel E3 ligases are discovered, the chemical effort to identify the best E3 ligase for a given target is exploding. Therefore, a genetic system to identify degradation-causing E3 ligases and suitable target/E3 ligase pairs is urgently needed. Here, we used the well-established dimerization of the FKBP12 protein and FRB domain by rapamycin to bring the target protein WDR5 into proximity with candidate E3 ligases. Strikingly, this rapamycin-induced proximity assay (RiPA) revealed that VHL, but not Cereblon, is able to induce WDR5 degradation - a finding previously made by PROTACs, demonstrating its predictive power. By optimizing the steric arrangement of all components and fusing the target protein with a minimal luciferase, RiPA can identify the ideal E3 for any target protein of interest in living cells, significantly reducing and focusing the chemical effort in the early stages of PROTAC development.